A Multicenter, Retrospective, Observational Study Evaluating Real-world Clinical Outcomes in Relapsing-remitting Multiple Sclerosis Patients Who Transition From Tysabri (Natalizumab) to Tecfidera (Dimethyl Fumarate)
Phase of Trial: Phase IV
Latest Information Update: 10 Oct 2015
Price : $35 *
At a glance
- Drugs Dimethyl fumarate (Primary) ; Natalizumab
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms STRATEGY
- Sponsors Biogen
- 28 Apr 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
- 22 Dec 2014 Planned End Date changed from 1 Sep 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 22 Dec 2014 Planned primary completion date changed from 1 Sep 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov.